Key result
A 14-day course of ganciclovir significantly reduced the incidence of CMV disease compared to CMV immunoglobulin (6% vs 40%, P=0.03) in CMV-seropositive heart transplant recipients receiving OKT3.
Why the study?
Does ganciclovir reduce CMV disease compared to CMV immunoglobulin in CMV-seropositive heart transplant recipients treated with OKT3?
Population
31 CMV-seropositive adult heart transplant recipients who received early immunoprophylaxis with OKT3…
Comparison
Ganciclovir 5 mg/kg administered intravenously… vs CMV immunoglobulin 100 mg/kg administered…
Design
RCT, Randomly assigned
Follow-up
6 months
Authors
Loading...
Supports ganciclovir over CMV immunoglobulin for prophylaxis in OKT3-treated heart transplant recipients; confirms RCT superiority in reducing CMV disease.
RCT (n=31)
Randomized
No
Does ganciclovir reduce CMV disease compared to CMV immunoglobulin in CMV-seropositive heart transplant recipients treated with OKT3?
Absolute Event Rate: 6% vs 40%
p-value: p=0.03
A 14-day course of ganciclovir is more effective than CMV immunoglobulin for preventing CMV disease in CMV-seropositive heart transplant recipients receiving OKT3 induction therapy.
Aguado et al. (1995) conducted an RCT in Cytomegalovirus (CMV) infection in heart transplant recipients (n=31). Ganciclovir vs. CMV immunoglobulin was evaluated on Development of CMV disease (p=0.03). A 14-day course of ganciclovir significantly reduced the incidence of CMV disease compared to CMV immunoglobulin (6% vs 40%, P=0.03) in CMV-seropositive heart transplant recipients receiving OKT3.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: